NVS vs TVTX: How Novartis AG and Travere Therapeutics Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: TVTX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVS and TVTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVS and TVTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025.

Full NVS guide

Travere Therapeutics (Nasdaq: TVTX) develops and sells treatments for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is a once-daily oral dual endothelin and angiotensin receptor antagonist that received full FDA approval for IgA nephropathy in September 2024 and, in April 2026, became the first FDA-approved therapy specifically for focal segmental glomerulosclerosis (FSGS). The company also sells THIOLA and THIOLA EC (tiopronin) for cystinuria, a small but steady legacy franchise, and partners FILSPARI outside the US with CSL Vifor in Europe and Everest Medicines in parts of Asia. Behind the commercial business sits a nephrology and metabolic pipeline led by pegtibatinase for classical homocystinuria and the in-licensed BTK inhibitor civorebrutinib for immune-mediated kidney diseases including primary membranous nephropathy.

Full TVTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
• TVTX drivers: The FSGS launch, a market with no prior approved therapy; Compounding the IgA nephropathy base.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. For TVTX, single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVS if you believe its drivers more; TVTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVS and TVTX guides.

NVS. Figures are approximate and qualitative, tied to the asOf date; verify live numbers before acting. The near-term picture is a revenue and profit dip as blockbusters lose exclusivity, so the stock is best judged on whether the newer growth brands and pipeline can restore mid-single-digit growth over the medium term rather than on a single trailing quarter.

TVTX. There is no meaningful P/E here because Travere is still running a small net loss, so the market is valuing it on the revenue trajectory and on how close FILSPARI gets to the stated $3B-plus peak ambition. The stock has moved violently in both directions over the past year, with a 52-week range of roughly $15.60 to $66.24, which tells you how much of the price is regulatory and launch expectation rather than trailing results. At ~10x sales with revenue nearly doubling in the lead product, the multiple is not extreme for a growth biotech but it does assume the launch curve holds.

Headline figures (approximate, Jul 2026): NVS shows revenue (ttm) Approximately $50 billion in annual net sales; Q1 2026 net sales were about $13.1 billion, down roughly 5% at constant currency on generic erosion, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix growing well above 50% at constant currency, offsetting Entresto's decline, margins/profitability High core operating margin, around 40% in 2025; 2026 guidance is for a low single-digit decline in core operating income on generic and R&D pressure, dividend Pays an annual dividend with a long record of increases; yield has recently been roughly 2%, subject to currency and Swiss withholding tax for ADR holders; TVTX shows revenue (ttm) ~$591M, up ~77% year over year, q2 2026 revenue ~$169.6M total, with FILSPARI US net sales of ~$141.1M (+96% YoY), net income (ttm) ~-$43M net loss (~$0.48 loss per share); Q2 GAAP loss ~$34.8M, gross margin (ttm) ~98.6%, with trailing free cash flow of ~$93M.

NVS and TVTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVS and TVTX exposure against your real portfolio. It is not an investment adviser.